Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karzinom, nicht kleinzellige lunge - antineoplastische mittel - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastische mittel - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tremelimumabum - konzentrat zur herstellung einer infusionslösung - tremelimumabum 25 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, dinatrii edetas corresp. natrium 0.012 mg, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1.25 ml. - hepatozelluläres karzinom - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tremelimumabum - konzentrat zur herstellung einer infusionslösung - tremelimumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, dinatrii edetas corresp. natrium 0.185 mg, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 15 ml. - hepatozelluläres karzinom - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karzinom, nicht kleinzellige lunge - antineoplastische mittel - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Europäische Union - Deutsch - EMA (European Medicines Agency)

teva b.v. - reslizumab - asthma - andere systemische medikamente für obstruktive atemwegserkrankungen, - cinqaero ist als zusatztherapie bei erwachsenen patienten mit schwerem eosinophilen asthma indiziert, die trotz hochdosierter inhalativer kortikosteroide und eines anderen arzneimittels zur erhaltungstherapie nicht ausreichend kontrolliert werden.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - reslizumabum - konzentrat zur herstellung einer infusionslösung - reslizumabum 100 mg, saccharum, natrii acetas trihydricus, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 1.41 mg. - zusatztherapie bei schwerem eosinophilem asthma bei erwachsenen - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - reslizumabum - konzentrat zur herstellung einer infusionslösung - reslizumabum 25 mg, saccharum, natrii acetas trihydricus, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 2.5 ml corresp. natrium 0.35 mg. - zusatztherapie bei schwerem eosinophilem asthma bei erwachsenen - biotechnologika